Some regulators, including the FDA, have a 50 percent efficacy threshold for emergency approval. CureVac is moving forward with its vaccine, though, and has highlighted its data showing the vaccine’s 53 percent efficacy rate in people ages 18-60. In that group, the vaccine protected against all hospitalization and death caused by COVID-19, and it provided 77 percent protection against moderate and severe COVID-19.
The vaccine uses mRNA technology like the vaccines produced by Pfizer and Moderna, but its storage requirements are easier to meet than the ultra-cold temperatures those two already-approved vaccines require.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
